Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

boehringer ingelheim ltd - olodaterol hydrochloride; tiotropium bromide - inhalation solution - 2.5microgram/1dose ; 2.5microgram/1dose

Jordan - engleski - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - tiotropium 2.5 mcg, olodaterol 2.5 mcg - 2.5 mcg, 2.5 mcg

Irska - engleski - HPRA (Health Products Regulatory Authority)

boehringer ingelheim international gmbh - tiotropium; olodaterol - inhalation solution - 2.5 µg/2.5 microgram(s) - anticholinergics; anticholinergics - drugs for obstructive airway diseases, adrenergics in combination with anticholinergics - it is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - olodaterol hydrochloride 0.0248%{relative} equivalent to to olodaterol 2.5mcg per actuation; tiotropium bromide monohydrate 0.0283%{relative} equivalent to to tiotropium 2.5mcg per actuation - solution for inhalation - 2.5mcg/2.5mcg - active: olodaterol hydrochloride 0.0248%{relative} equivalent to to olodaterol 2.5mcg per actuation tiotropium bromide monohydrate 0.0283%{relative} equivalent to to tiotropium 2.5mcg per actuation excipient: benzalkonium chloride disodium edetate hydrochloric acid purified water - spiolto respimat is indicated for the long term, once daily maintenance treatment in patients with copd (including chronic bronchitis and emphysema), to reduce airflow obstruction, to improve quality of life, and to reduce associated dyspnoea.

Izrael - engleski - Ministry of Health

boehringer ingelheim israel ltd. - olodaterol as hydrochloride; tiotropium bromide as monohydrate - solution for inhalation - olodaterol as hydrochloride 2.5 mcg; tiotropium bromide as monohydrate 2.5 mcg - vilanterol and umeclidinium bromide - spiolto respimat is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).